J&J is screening its antiviral compounds, including darunavir, for potential activity against the novel coronavirus. Credit: Open Grid Scheduler / Grid Engine.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Johnson and Johnson (J&J) have noted the lack of evidence that its HIV drug darunavir has antiviral activity against SARS-CoV-2, the novel coronavirus that causes Covid-19.

Currently, HIV protease inhibitors are being considered as potential treatments for the new viral infection. J&J says that the use supports limited, unpublished virologic and clinical data in SARS coronavirus patients.

Darunavir is a protease inhibitor marketed by the company’s unit Janssen Pharmaceutical. The drug has approval as a boosting agent for use in combination with other antiretrovirals to treat HIV-1.

Janssen does not have any clinical nor pharmacological evidence allow the inclusion of darunavir / cobicistat in Covid-19 treatment guidelines.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Furthermore, there are no published safety and efficacy data of darunavir / cobicistat in Covid-19 patients.

To date, no in-vitro studies or clinical trials took place to assess the safety and efficacy of darunavir / cobicistat or darunavir / cobicistat / emtricitabine / tenofovir alafenamide for coronavirus treatment.

In a statement, J&J said: “Johnson & Johnson has no evidence that darunavir has any effect against SARS-CoV-2, the virus that causes Covid-19.

“Johnson & Johnson is screening its antiviral compounds, including darunavir, to determine potential in vitro effect against SARS-CoV-2. We are partnering with multiple organisations to support the development of research programmes and fast-track solutions for Covid-19.”

Janssen provided darunavir-based medicines for three clinical studies in China.

 

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact